SYDNEY, Dec. 9, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share top-line final data from its phase I study of Cantrixil (TRX-E-002-1) in patients with persistent or recurrent ovarian cancer (NCT02903771).
Key Points
What do Aussie businesses need to do to keep up? There has been mounting chatter that AI is growing even faster than the rapid acceleration we sa...
The holiday season brings a surge of online activity for small and medium businesses (SMBs), with increased sales and customer inquiries offering ...
In recent years, it is said that more and more people are searching for properties online than those who visit real estate companies in person. For ...
Do you want your website to rank higher in the top results of the Google search engine? Then hire the excellent SEO Services in Australia for your n...
As Australia enters another long, hot and potentially destructive summer, businesses and residents are preparing for the natural disasters synonym...
The new platform brings an innovative approach to unite office-based and desk-less teams 8seats, a next-generation messaging platform for busine...
